Deals
A mostly black box since emerging with more than a billion dollars in hand, Xaira Therapeutics is slowly pulling back the curtain, revealing plans to find partners and validate its pipeline.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
On 6 December 2019, Recipharm AB, through its directly wholly-owned subsidiary Recipharm Holdings Limited, published an offer document setting out the full terms and conditions of its recommended cash offer to acquire the entire issued and to be issued share capital of Consort Medical plc.
Grey Wolf targets ERAP antigen presentation pathways with the aim of ‘illuminating’ non-responsive tumors for attack and destruction by the immune system
What’s New at the J.P. Morgan Life Healthcare Conference?
Consulting firm EY released its annual report on mergers and acquisitions (M&A) to coincide with the JP Morgan Healthcare conference this week. For 2019, EY indicates there were $357 billion in life science deals, an “all-time record,” surpassing the previous high in 2014.
Not waiting for the start of the annual J.P. Morgan Healthcare Conference, Eli Lilly announced it will acquire California-based Dermira, Inc. in an all-cash deal for $1.1 billion.
It can be a bit difficult to predict exactly what the big stories out of the JP Morgan Healthcare Conference are going to be. There’s no telling if some surprise deal will take the air out of the room, but here’s a look at some of the top presentations.
Funding to Support Ongoing Advancement of siFi2, Lead Candidate from Company’s First-of-its-Kind Platform for Precisely Controlling Core Cell Migration Mechanisms
The Novo Holdings REPAIR Impact Fund announced a EUR 7 million investment in Mutabilis, a company developing novel antibacterials against Gram-negative infections based near Paris, France.
The clinically integrated ancillary care platform will accelerate expansion into local gastroenterology (GI) practices to provide specialized care for the rising NonAlcoholic SteatoHepatitis (NASH) epidemic
Expedeon AG announced the closing of the sale and purchase agreement with Abcam plc, Cambridge, UK, for the sale of the Company’s proteomics and immunology business, as announced on November 11, 2019 and as approved by the Extraordinary Shareholder Meeting on December 19, 2019.